Hims & Hers Health (HIMS) shares were down more than 3.5% in Friday's premarket activity after closing down 7.7% on Thursday following a US Food and Drug Administration determination that a shortage of Eli Lilly's (LLY) popular weight loss drug tirzepatide has ended.
Hims & Hers Health was allowed to produce its version of the drug as long as the FDA determined there was a shortage.
The FDA said in a letter on Thursday that "the tirzepatide injection product shortage is resolved."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments